Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 9 | BMC Cancer

Fig. 9

From: Comprehensive network pharmacology and experimentation to unveil the therapeutic efficacy and mechanisms of gypenoside LI in anaplastic thyroid cancer

Fig. 9

Gyp LI inhibits the migration and invasive ability of ATC cells. (A-C) The Transwell migration assay was used to evaluate the migration capability of ATC cells through the chamber following treatment with Gyp LI. Following treatment with Gyp LI (0, 20, 40, and 60 µM), the mean numbers of 8305 C cells migrating through the chamber were 141.67, 97, 65.67, and 35.67, respectively. Similarly, the mean numbers of C643 cells migrating through the chamber were 176, 92.33, 68.33, and 36.33, respectively. (Magnification: 20×; scale bar = 500 μm). (D-F) The Matrigel Transwell invasion assay was used to evaluate the invasive capability of ATC cells through the basement membrane following treatment with Gyp LI. Following treatment with Gyp LI (0, 20, 40, and 60 µM), the mean numbers of 8305 C cells that migrated through the Matrigel-coated chambers were 173.67, 155.33, 111.33, and 84.33, respectively. Similarly, the mean numbers of C643 cells that migrated through the Matrigel-coated chambers were 149.67, 139, 86.67, and 53.67, respectively. (Magnification: 20×; scale bar = 500 μm)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us